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Abbreviation 
APCI Atmospheric Pressure Chemical Ionization 
AT- all trans- 
Bas basophil 
BN rat Brown Norway rat 
CNS central nervous system 
D1 dopamine 1 receptor 
D2 dopamine 2 receptor 
Eos eosinophil 
ERG electroretinogram 
H&E hematoxylin and eosin 
Hct hematocrit 
Hgb hemoglobin 
LUC large unstained cell 
Lym lymphocyte 
MCH mean corpuscular hemoglobin 
MCHC mean corpuscular hemoglobin concentration 
MCV mean corpuscular volume 
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Mon monocyte 
MRM multiple reaction monitoring 
Neu neutrophil 
OPs oscillatory potentials 
PDE phosphodiesterase 
Plt platelet 
RAR retinoic acid receptor 
RAREs retinoic acid response elements 
RBC red blood cell 
Ret reticulocyte 
RXR retinoid X receptor 
VAD vitamin A deficiency 
Vit A vitamin A 
Vit A (–) diet AIN93G-Vitamin A (–) 
Vit A (+) diet AIN93G 
WBC white blood cell 
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CHAPTER I 
Preface 
 
 
Vitamin A which is a fat-soluble vitamin is also called retinoid and has three active 
forms (retinal, retinol, and retinoic acid) in the body.  The active forms of retinoid 
plays an essential role in numerous biological processes, including vision, cellular 
proliferation, differentiation, organ development, and immunity (1, 2).  Therefore, loss 
of retinoids, known as vitamin A deficiency (VAD) disease, induces a variety of 
symptoms.  Visual impairment is one of the typical symptoms of VAD disease.  In the 
eye, loss of retinoid mainly influences development or maintenance of the retina (2).  
Retinoids delivered to the retina, as all-trans (AT-) retinol, enter the outer segments of 
the photoreceptor cells where it is transformed to 11-cis retinal, known as chromophore, 
and combined with the opsin to form the light sensitive rhodopsin (3).  The 11-cis 
retinal is isomerized to AT-retinal by absorption of a photon and released from the 
rhodopsin in order to activate downstream molecules, such as transducin and 
phosphodiesterase (PDE), related to photo-transduction (4).  Because this is the first 
reaction in phototransduction, loss of retinoids in retina induces photoreceptor cell 
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dysfunctions and causes visual abnormalities consisting of prolonged dark adaptation or 
night blindness with disintegration of the outer segments of photoreceptor cells (5).  
Therefore, it is very important for patients with VAD to understand functions of 
photoreceptor cells.  In order to evaluate the function of photoreceptor cells and 
diagnose visual impairment by VAD, electroretinogram (ERG) recording is both 
clinically and non-clinically useful.  Although the retina is constituted from several 
cell layers remaining each different function, ERG recording enables to evaluate 
function of each retinal cell layer, separately (Fig I-1).  For example, the function of 
photoreceptor cells can be assessed by measuring amplitude or implicit time of peak of 
ERG a-wave (3).  In human and animals with VAD, ERG is reported to show that 
a-wave reduces depending upon the stage of the disease (3, 5).  As above described, 
effects of VAD on the function, histology, or ERG a-wave have been well investigated 
and clarified to date.  On the other hand, there is a symptom which could not be 
explained only by photoreceptor dysfunctions in VAD disease.  Previous studies have 
reported some patients with VAD resulting from intestinal diseases sometimes show 
reduced contrast sensitivity (6).  Contrast sensitivity is the visual ability to see objects 
that may not be outlined clearly or that do not stand out from the background (7).  
Reduced contrast sensitivity is also noted in patients with diabetes, Parkinson disease, 
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or cataract (8, 9) and may cause decreased visual function in spite of normal visual 
acuity.  Previous studies have demonstrated that ERG in patients with diabetes shows 
changes in oscillatory potentials (OPs) correlating with reduced contrast sensitivity (8).  
OPs, one of the ERG components, is reflecting activities of inner retinal layer cells 
including amacrine and ganglion cells (3), shown as Fig I-1.  The inner retinal layer 
cells function in visual transduction between outer retinal layer cells to optic nerve 
through some neurotransmitters including dopamine, gamma-aminobutyric acid 
(GABA), glycine, acetyl choline, and so on (10).  Recently, Gastinger MJ et al. 
reported that cholinergic and dopaminergic amacrine cells are lost during the early 
stages of retinal neuropathy in diabetic mouse model (11).  This report suggests 
amacrine cell dysfunctions are implicated in reduced contrast sensitivity.  However, 
there is no article explaining relationships between VAD disease and amacrine cell 
function or OPs. 
On the other hand, retinoic acid receptor (RAR) and retinoid X receptor (RXR) which 
mediate effects of active form of retinoids are known to express in inner retinal layer 
cells including amacrine cells (12, 13).  AT-retinoic acid or 9-cis retinoic acid which 
are active forms of retinoid regulate dopamine pathways in the central nervous systems 
(CNS) by binding to these receptors (14).  Dopamine receptors have been reported to 
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express in retinal cells including amacrine cells (15, 16).  These suggest that retinoids 
have something rolls in visual transduction of not only photoreceptor but also the 
amacrine cells possible through dopamine pathways.  Therefore, I estimated that loss 
of retinoid may influence the function of amacrine cells as well as photoreceptor cells 
and induce reduced contrast sensitivity with changes in OPs in ERG recording.   
In the present study, in order to investigate the effects of VAD on amacrine cell 
function, I firstly produced a VAD model by feeding to rats vitamin A deficient (Vit A (-)) 
diet (CHAPTER II).  Subsequently, retinal functions of amacrine cells as well as 
photoreceptor cells were electro-physiologically evaluated by ERG recording.  Then, I 
also investigated the involvement of dopamine pathway in retinal function or visual 
transduction using the VAD model (CHAPTER III). 
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Figures 
Figure. I-1 Diagram of retinal cell layer and ERG components reflecting functions 
or activities or each cells (Modified from Nature Reviews Neuroscience 2, 333-342 
(May 2001)). 
 
When light enters to retina, the light energy changes shape of retinal (from 11-cis retinal 
to AT-retinal) binding to rhodopsin.  This change in shape begins a cascade of events 
that result in a change in the voltage across the membrane of the photoreceptor 
(hyperpolarization).  Thus, photoreceptor cells become negatively charged when 
stimulated by light, and its function is exhibited by negative wave as a-wave in ERG.  
Once the photoreceptor cell has transduced the light to the change in membrane 
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potential, it then conveys this by its synapse onto a bipolar cell.  The bipolar cells 
receive information from photoreceptors, and their axons transmit information to the 
amacrine or ganglion cells.  Under dark adaptation, the photoreceptor cell stimulates 
depolarizing bipolar cells, as called ON bipolar cell, which releases K+.  The K+ is 
received by Muller cells which across all layer of the retina, and course from outer side 
to inner side of the retina.  Therefore, function of bipolar cells is reflected by a positive 
wave as b-wave in ERG.  OPs consisting of approximately four wavelets have 
physiologic origin that differs from the a- and b-waves.  Activity of inhibitory 
feedback circuits in the inner retinal layer including amacrine cells as the origin of OPs 
has been proposed (3, 17). 
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CHAPTER II 
Establishment of Rat Model with Early Vitamin A 
deficiency Disease and Notification of Dysfunction of 
Inner Retinal Layer Cells. 
 
 
1. SUMMARY 
In the present study, rat model with early VAD disease was produced in order to 
investigate the visual impairments by loss of retinoid.   
VAD state was produced by feeding a Vit A deficient diet to Brown Norway rats for 
10 weeks.  The effects of VAD were analyzed by evaluating the retinoid levels in 
plasma and retina.  Retina was investigated by ophthalmological and histopathological 
examination at Week 10 or after a 5 week recovery period.  Other examinations 
including clinical observation, body weights, food consumption, and hematology were 
also conducted.   
VAD was detected first as a decrease in plasma all-trans retinol at Week 6.  A 
reduced body weight gain with slight decrease in food intake, peri-papillary 
opacification indicative of papilledema without histopathologic changes were also 
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observed, known as early symptoms of VAD.  After 5 weeks of recovery, body weight 
gain and food intake returned to control levels. 
The findings observed in the present study are known as early symptoms of VAD.  
Therefore, the present VAD rat model without severe physical condition was considered 
to be appropriate to detect primary effects of VAD on retinal function. 
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2. INTRODUCTION 
The Effects of VAD on retinal function and general condition in rats have been reported 
by several studies.  Dowling JE et al. has reported that a small a-wave and a slight 
reduction of b-wave in ERG recording are induced by feeding albino rats a Vit A 
deficient diet for 8 weeks (5).  In that study, the VAD rats showed no measurable 
retinoid in the blood and decreased body weight gain from approximately 4 to 5 weeks 
after initiation of feeding Vit A deficient diet.  By the beginning of the 8 week, body 
weight loss, xerophthalmia, xerosis, and keratomalacia were observed.  The other 
research has explained that the body weight gain is a sensitive indicator of Vit A status 
and serum Vit A levels below 20 ng/mL signify an adequate stage of deficiency to 
conduct the experiment (17).  Although it is necessary to provide low retinoid level, 
progressive stage of VAD may influence general conditions in rats and induces 
secondary changes in retinal functions by poor physical conditions.  Accordingly, 
monitoring general condition including body weights was very important to avoid 
occurrence of severe physical condition and to make an appropriate VAD model for 
evaluation the primary effects of VAD on retinal function.  Therefore, I conducted 
general observation including clinical observation and measurement of body weights, 
food consumption, and plasma AT-retinol, and hematology.  Ophthalmologic 
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examination was also done before notification of body weight loss or decline in plasma 
AT-retinol.  Reversibility of these parameters was also evaluated after the 5 week 
recovery period. 
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3. MATERIAL AND METHODS 
3.1. Animals 
Thirty six male Brown Norway (BN) rats were purchased at 21 days of age from 
Charles River Laboratories International, Inc.  Both eyes of all rats were checked by 
slit lamp and binocular indirect ophthalmoscope at pretreatment period.  Rats which 
had no abnormal findings in both eyes were selected and divided into VAD and control 
groups.  A diet with or without Vit A was fed to the control and the VAD group, 
respectively.  An AIN93G, Vit A (+) diet, or an AIN93G-Vitamin A (–), Vit A (–) diet, 
were used.  Both feed diets were obtained from Oriental Bio service Kanto.  
Compositions of the diets were showed in Table II-1, II-2, and II-3.  Each animal was 
housed individually in a stainless steel cage, in a clean air room with a 12-hour 
light/dark cycle.  The room had controlled illumination (less than 100 lux), 
temperature (23 to 24 C), and humidity (53% to 71%).  This study was performed in 
compliance with Laboratory Animal Policy at Eisai, and was approved by the 
Laboratory Animal Care and Use Committee at Eisai Co., Ltd.  All procedures were 
performed according to the ARVO Statement for the Use of Animals in Ophthalmic and 
Vision Research. 
3.2. Study design 
The first week of feeding the Vit A (–) diet was defined as Week 1.  To make VAD rats, 
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the Vit A (–) diet was fed to 18 male BN rats for 10 weeks.  Subsequently, Vit A (+) 
diet was fed for 5 weeks (Week 11 to 15) in order to examine recovery from VAD.  
The Vit A (+) diet was given to 18 males in a control group for 15 weeks.  In both VAD 
and control groups, each 12 main study and 6 recovery rats were euthanized at Weeks 
10 and 15, respectively, by exsanguination from the abdominal aorta under isoflurane 
anesthesia, for sampling of eyes.  After euthanasia, the retina was collected.  
Euthanasia to collection of the retina was carried out under dim red light.  All animals 
were weighed weekly.  Blood was collected from the jugular vein of each of 12 rats 
(euthanized at Week 10) at Weeks 6, 8, and 10 to measure plasma concentration of 
AT-retinol.  Prior to euthanasia, ophthalmologic examination was performed on all 
surviving rats.  At Week 10, each of 6 right retinas in both VAD and control groups 
were used for the measurement of retinoids.  The retinal retinoids were also measured 
using each of 6 right retinas in both groups at Week 15.  Each of 6 left eyes in both 
groups was applied on histopathologic examination. 
3.3. General observations 
All surviving animals were observed for clinical signs at least once a day and weighed 
weekly throughout experimental period.  Amount of residual food was also recorded 
once a week. 
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3.4. Hematology 
At necropsy, blood samples were collected from the jugular vein under isoflurane 
anesthesia using EDTA-2K as anticoagulant.  The following parameters were 
examined. 
Parameter (Abbreviation) Method 
Red blood cell (RBC) Laser flow cytometric methoda 
Hematocrit (Hct) Laser flow cytometric methoda 
Hemoglobin (Hgb) Modified cyanmethemoglobin methoda 
Mean corpuscular hemoglobin (MCH) Laser flow cytometric methoda 
Mean corpuscular volume (MCV) Laser flow cytometric methoda 
Mean corpuscular hemoglobin concentration 
(MCHC) 
Laser flow cytometric methoda 
White blood cell (WBC) Laser flow cytometric methoda 
Differential WBC* 
*Basophil (Bas), Eosinophil (Eos), 
Lymphocyte (Lym), Monocyte (Mon), 
Neutrophil (Neu), and Other (Large unstained 
cell [LUC]) 
Peroxidase method and Laser flow 
cytometric methoda 
Platelet (Plt) Laser flow cytometric methoda 
Reticulocyte (Ret) Laser flow cytometric methoda 
a: ADVIA 120 Hematology System, Siemens Health Care Diagnostics 
 
3.5. Retinoid determinations in Plasma and Retina 
Reagents and standard derivatives 
HPLC-grade solvents and reagents, acetonitrile, methanol, propanol, and formic acid 
were purchased from Wako Pure Chemicals (Osaka, Japan).  Ultra-pure water was 
prepared by using Millipore Milli-Q TOC system (Billerica, MA, US).  The standard 
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reagent of retinyl acetate was obtained from Cica reagent (Tokyo, Japan).  Internal 
standard solutions (1 mg/mL) were prepared in acetonitrile.  To prepare working 
sample solutions for LC-MS, retinyl acetate stock solution was diluted to a final 
concentration of 5.0 µg/mL. 
 
Liquid chromatography/mass spectrometric analysis 
An Applied Biosystems AB5000 mass spectrometer (Foster City, CA, US) with a 
SHIMADZU prominence UFLC (Kyoto, Japan) was used as the LC-APCI-MS system.  
The Waters Shield RP18 (2.0 x 150 mm) (Milford, MA, US) with Phenomenex security 
guard (C18, 2.0 x 4.0 mm) (Torrance, CA, US) was selected as the stationary phase.  
The composition of mobile phase A was water/acetonitrile/formic acid (95:5:0.1) and 
mobile phase B was propanol/acetonitrile (80:20).  Linear gradients of mobile phase B 
were as follows: 0 min-1%, 0.5 min-1%, 1.5 min-25%, 30 min-99 %, 33 min-99%, 
33.1 min-1%, 40 min-stop.  The flow rate of the mobile phase was 250 µL/min with 
450 µL/min of post-column addition of Methanol.  AB5000 mass spectrometer was 
used in Atmospheric Pressure Chemical Ionization (APCI) - multiple reaction 
monitoring (MRM) mode.  Each condition of MRM channel is listed below. 
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Retinoids 
Q1 
(Da) 
Q2 
(Da) 
Dwell time
(msec) 
DP 
(volts) 
CE 
(volts) 
CXP 
(volts) 
Retinol (retinol esters) 269.2 93.2 150 66 27 12 
Retinal 285.1 161.3 150 71 15 18 
Retinoic acid 301.2 123.3 150 66 25 18 
CE: Collision Energy, CXP: Collision Cell Exit Potential, DP: Declustering Potential 
Most of the sample pretreatment process was done under dim red light.  For the 
plasma sample pretreatment, 50 µL of plasma samples were moved to shaded brown 
tubes (1.5 mL) and mixed with 190 µL of acetonitrile and 10 µL of 5.0 µg/mL retinyl 
acetate in acetonitrile.  Mixed solutions were centrifuged 9500 × g for 20 min.  The 
supernatant was moved to a plastic vial.  For the tissue sample pretreatment, retina was 
homogenized in 2.0 mL of water/acetonitrile (25:75).  A hundred µL of 5.0 µg/mL 
retinyl acetate in acetonitrile was added to 2.0 mL of tissue homogenates.  Two 
hundred and fifty uL of samples were moved to shaded brown tubes (1.5 mL).  Mixed 
solutions were then centrifuged at 8600 × g for 20 min.  Supernatants were moved to 
shaded plastic vials.   
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The amount of plasma retinoid was calculated based on the amount of retinyl acetate.  
X-cis retinal includes 11- or 13-cis retinal in this study, because it was technically 
difficult to measure the retinal, separately.   
3.6. Ophthalmologic examination 
The ophthalmologic examinations with slit lamp or binocular indirect ophthalmoscope 
were performed on both eyes of all animals at pretreatment period and Weeks 10 and 15.  
Before observation, the pupils were dilated by topical application of 0.5% tropicamide 
and 0.5% phenylephrine hydrochloride (Mydrin®-P, Santen Pharmaceutical Co., Ltd., 
Osaka, Japan).  Fundus was photographed by a Kowa RC-2 fundus camera (Kowa, 
Tokyo, Japan).   
3.7. Histopathologic examination 
Each of 6 left eyes in both control and VAD groups was preserved in 
glutaraldehyde-formaldehyde and processed to slide for microscopic examination of 
paraffin embedded sections stained with hematoxylin and eosin (H&E) at Weeks 10 and 
15.  
3.8. Statistical analysis 
Student’s t-test were repeated for comparison of the body weights, food consumption, 
and concentration of plasma retinoid.  Concentration of retinal retinoids was analyzed 
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with Student’s t-test.  In each analysis, differences were considered to be significant 
when P < 0.05.   
24 
 
4. RESULTS 
4.1. General observations  
Body weights and food consumption within the study period are shown in Figure II-1 
and II-2.  Significantly lower body weights with slight decrease in food consumption 
were observed from Week 8 in VAD rats.  During the recovery period, body weights of 
VAD rats increased with similar growth rate compared to the control group.  However, 
the difference in body weights between the control and VAD rats at Week 10 (44.5 g) 
was maintained at Week 15 (55.3 g).  Food consumption was comparable to control 
levels during recovery periods.  At clinical observation, there was no adverse clinical 
sings throughout the experimental period. 
4.2. The concentration of plasma all trans-retinol  
Concentration of plasma AT-retinol is shown in Figure II-3.  The plasma AT-retinol 
levels in the control group were stable throughout the experimental period of 6 to 
10 weeks with the average concentration of about 800 ng/mL (minimal–maximal 
concentrations: 576–1012 ng/mL).  At Week 6, in the VAD group, the average 
concentration of plasma AT-retinol decreased to 393 ng/mL (min–max: 261–516 ng/mL).  
The average plasma concentrations of AT-retinol in VAD rats decreased further to 
100 ng/mL (min–max: 57–161 ng/mL) and 36 ng/mL (min–max: 30–44 ng/mL) at Week 
8 and 10, respectively. 
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4.3. Retinal retinoids 
The levels of all measurable retinal retinoids were significantly lower in VAD rats than 
those of control rats at Week 10 (Figure II-4 (a)).  AT-retinol, AT-retinal, and 
AT-retinoic acid in VAD group decreased by about 50% or less.  Meanwhile, 9-cis 
retinol and retinal decreased by 85% and 54%, respectively.  X-cis retinal containing 
11- and 13-cis retinal decreased by 46%.  These changes have almost returned to 
control levels at Week 15 (after 5 week recovery period) (Figure II-4 (b)).  
4.4. Hematology 
The results of hematology at Week 10 and 15 were summarized in Table II-4.  There 
were no changes in hematologic parameters. 
4.5. Ophthalmologic examination 
Binocular indirect ophthalmoscope observation of the fundus revealed peri-papillary 
opacification, and was found in all VAD rats at Week 10 (Table II-5 and Figure II-5).  
At Week 15, the region of opacification tended to become smaller, but did not disappear.  
There were no other VAD related changes in anterior and posterior chambers and optic 
media during the experimental period. 
4.6. Histopathologic examination 
Each of the 6 left eyes of control and VAD rats were histopathologically observed at 
Weeks 10 and 15 under H&E staining.  There were no findings in the retina including 
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photoreceptor cells, inner retinal layer cells, and papilla. 
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5. DISCUSSION 
In VAD group, feeding a Vit A deficient diet to rats was stopped at Week 10, because 
reduced body weight gain which is thought as a good marker for VAD state in rats (17) 
was observed with slight decrease in food consumption in VAD rats at Weeks 8 to 10.  
At Week 10, retinoid level in plasma and retina also significantly decreased.  For these 
reasons, Vit A deficient period for 10 weeks is considered appropriate to induce low 
VAD state in BN rats.  Also, peri-papillary opacification was noted in all VAD rats at 
ophthalmologic examination.  This finding is considered to be one of the properties of 
papilledema (18).  In VAD animals, occurrence of papilledema is reported as a result 
of increased cerebrospinal fluid pressure (19).  These results indicate that VAD disease 
was certainly induced in BN rats given Vit A (-) diet for 10 weeks and a VAD model 
was successfully established in the present study.   
The VAD model is considered to be with no severe physical condition, because there 
was not body weight loss, adverse VAD-related clinical sings, or changes in 
hematologic parameters throughout the experimental period.  In addition, there were 
not histopathologic changes in the retina of VAD rats and xerophthalmia, xerosis, or 
keratomalacia indicative of an advanced VAD state (5).  In the previous study, albino 
rats given Vit A deficient diet for 8 weeks showed disintegration of outer segment of 
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photoreceptor cells.  The discrepancy can be explained by difference between 
accessibilities of retinal damage of pigmented or non-pigmented species.  Generally, 
ocular melanin may protect the retina, probably by the absorption of light.  Because of 
this, albino rat retinas are particularly more sensitive to the deleterious effects than 
pigmented rat retinas (20). 
Decreased retinal retinoids and body weight gain with food consumption observed up to 
Week 10 were comparable to control levels after feeding Vit A (+) diet to the VAD rats 
for 5 weeks.   
These results indicate that the VAD rats in the present study were considered to be in 
a reversible and early stage of VAD disease and have an appropriate state to investigate 
the primary effects of VAD on retinal function.   
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6. FIGURES AND TABLES 
Table II-1. Composition of AIN-93G (per 100 g) 
 Vitamin Free Casein 20.00000 g
 L-cystine 0.30000 g
 Cornstarch 39.74860 g
 αCornstarch 13.20000 g
 Sucrose 10.00000 g
 Soybean oil 7.00000 g
 Cellulose 5.00000 g
 AIN-93G mineral mixture 3.50000 g
 AIN-93 vitamin mixture 1.00000 g
 Choline bitartrate 0.25000 g
 tert-butylhydroquinone 0.00140 g
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Table II-2. Composition of AIN-93G Vitamin A (-) (per 100 g) 
 Vitamin Free Casein 20.00000 g
 L-cystine 0.30000 g
 Cornstarch 39.74860 g
 αCornstarch 13.20000 g
 Sucrose 10.00000 g
 Soybean oil 7.00000 g
 Cellulose 5.00000 g
 AIN-93G mineral mixture 3.50000 g
 AIN-93 vitamin mixture (w/o Vitamin A) 1.00000 g
 Choline bitartrate 0.25000 g
 tert-butylhydroquinone 0.00140 g
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Table II-3. Composition of AIN-93 vitamin mixture (per 100 g) 
 Vitamin D3(400000 IU/g) 0.02500 g
 Vitamin E (50%) 1.50000 g
 Vitamin B1 0.06000 g
 Vitamin B2 0.06000 g
 Vitamin B6 0.07000 g
 Vitamin B12 (0.1%) 0.25000 g
 Vitamin K1 0.00750 g
 d-Biotin 0.00200 g
 Folic acid 0.02000 g
 Ca-Panthothenate 0.16000 g
 Niacin 0.30000 g
 Sucrose 97.54550 g
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Table II-4. Hematology in control and vitamin A deficient rats.  
Week 10 
 RBC Hgb Hct MCV MCH MCHC Ret WBC 
Unit 106 /uL g/dL % fL pg % 109 /uL 103 /uL
Mean 
value 
Control 7.88 13.3 41.0 52.0 16.9 32.5 176.7 18.19 
VAD 8.74 14.3 44.3 50.7 16.4 32.3 141.1 17.33 
 Neu Lym Mon Eos Bas ULC Plt  
Unit 103 /uL 103 /uL 103 /uL 103 /uL 103 /uL 103 /uL 103 /uL  
Mean 
value 
Control 1.26 15.75 0.32 0.47 0.10 0.29 831  
VAD 2.92 13.47 0.24 0.16 0.09 0.45 1052  
Week 15 
 RBC Hgb Hct MCV MCH MCHC Ret WBC 
Unit 106 /uL g/dL % fL pg % 109 /uL 103 /uL
Mean 
value 
Control 8.07 13.1 40.8 50.6 16.3 32.2 226.1 15.27 
VAD 8.09 13.1 41.3 51.0 16.2 31.8 297.2 15.52 
 Neu Lym Mon Eos Bas ULC Plt  
Unit 103 /uL 103 /uL 103 /uL 103 /uL 103 /uL 103 /uL 103 /uL  
Mean 
value 
Control 1.78 12.48 0.32 0.37 0.06 0.26 815  
VAD 1.38 13.33 0.30 0.22 0.07 0.22 897  
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Table II-5. Summary of peri-papillary opacification at Week 10 and 15  
 Control group VAD group 
Week 10   
Right eye 0/18 18/18 
Left eye 0/18 18/18 
Week 15   
Right eye 0/6 6/6 
Left eye 0/6 6/6 
Peri-papillary opacification found at Weeks 10 and 15 are summarized in 
this table. 
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Figure II-1.  Comparison of body weight between control and vitamin A deficient 
rats. 
 
Plots of body weight for control and vitamin A deficient rats during experimental period.  
Mean values of 18 rats are shown.  Bars, SD.  *: p<0.05  **: p<0.01 
 
** 
* 
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Figure II-2.  Comparison of food consumption between control and vitamin A 
deficient rats. 
 
Plots of food consumption of control and vitamin A deficient rats during experimental 
period.  Mean values of 18 rats are shown.  Bars, SD.  *: p<0.05  **: p<0.01 
** 
* 
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Figure II-3.  Comparison of plasma all-trans retinol between control and vitamin 
A deficient rats. 
Plots of concentration of plasma all-trans retinol for control and vitamin A deficient rats 
at Weeks 6, 8, and 10.  Mean values of 12 rats are shown.  Bars, SD.  **: p<0.01 
 
** 
** 
** 
37 
 
Figure II-4.  Comparison of retinoids in retina between control and vitamin A 
deficient rats.  
 
(a) The ratios of measurable retinal retinoids in retina of vitamin A deficient (n=6) rats 
at Week 10 to those of control (n=6) are shown.  (b) The ratios of retinal retinoids 
in vitamin A deficient rats at Week 15 to those of control rats are shown.  Bars, SD.  
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*: p < 0.05, **: p < 0.01 versus control with student’s t-test.  
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Figure II-5.  Fundus photographs at Week 10.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(a) and (b) show fundus photographs in control and VAD rats, respectively. 
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CHAPTER III 
Investigation of Retinal Function of the Vitamin A Deficient 
Rat model and Involvement of Dopamine Pathway in Inner 
Retinal Layer Cell Functions. 
 
1. SUMMARY 
As I described in CHAPTER I, I hypothesized that loss of retinoid influences the 
function of amacrine cells as well as photoreceptor cells and induce reduced contrast 
sensitivity with changes in OPs in ERG recording.  In order to verify the hypothesis, I 
electro-physiologically investigated retinal functions of the VAD model produced in 
CHAPTER II in the present study.  As the result, ERG recording at Week 10 showed 
reduced OPs as well as a- and b-waves at multi-intensities of light stimulation.  Further 
analysis indicated that the ratio of the changes in OPs was more significant than those of 
a- and b-waves.  After 5 weeks of recovery, these changes returned to control levels.  
These results suggest that inner retinal cell functions which are reflected in OPs were 
reduced by VAD.  OPs are considered to become more sensitive markers of visual 
impairment by VAD since the rat model is in early stage of VAD disease. 
Subsequently, I compared expression of dopamine receptors and locomotor activity, 
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as an alternative indicator of dopamine pathway activity, between control and the VAD 
model with reduced OPs in order to investigate the involvement of dopamine pathway 
in function of inner retinal layer cells.  Although comparison of locomotor activity 
showed decreased rearing count in the VAD rats, there was no significant reduction in 
the VAD rats in analysis of gene expression of dopamine receptors.   
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2. INTRODUCTION 
Retinal Function of the Vitamin A Deficient Rat model 
ERG in laboratory animals with VAD has been recorded in previous studies.  In an 
analysis of ERG with multi-intensity of light stimulus (light intensity: 0.02 to 
2000 cds/m2), the b-wave was greatly reduced at less than approximately 20 cds/m2 of 
light intensity, and the a-wave was barely perceptible even at the highest light intensity 
by feeding albino rats a Vit A deficient diet for 8 weeks in a previous report (5).  In 
that study, disintegration of outer segment of the photoreceptor cell was 
histopathologically observed, and there were body weight loss, xerophthalmia, xerosis, 
or keratomalacia indicative of an advanced VAD state.  Severe physical condition 
generally induces decreased blood circulation and reduces the supply of nutrients to eye, 
and then may secondary affect ERG components.  Therefore, I electro-physiologically 
analyzed retinal function in the VAD model without severe physical condition under the 
latest protocol recommended by ISCEV in order to investigate the primary effect of 
VAD on retinal function (21). 
 
Involvement of Dopamine Pathway in Inner Retinal Layer Cell Functions 
Subsequently, I researched mechanisms of effects of VAD on function of inner retinal 
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layer cells.  The inner retinal layer cells function in visual transduction between outer 
retinal layer cells to optic nerve through some neurotransmitters including dopamine, 
GABA, glycine, acetyl choline, and so on (10).  On the other hand, retinoic acid, one 
of the active forms of retinoid, is known to be implicated in regulation of gene 
expression.  The retinoic acid is mediated primarily by two families of nuclear 
hormone receptors, RAR and RXR (18).  RAR can be activated by AT-retinoic acid 
and 9-cis retinoic acid, while RXR is activated by 9-cis retinoic acid.  Activated 
retinoid receptors function as transcription factors, activating specific retinoic acid 
response elements (RAREs) for transcriptional regulation of target genes.   
Dopamine receptor is one of the genes have the RAREs in the promoter region and is 
known to be regulated by retinoic acid (22, 23, 24).  Dopamine receptors are present in 
the amacrine cells and are known to be involved in visual signal transduction (6, 23, 24, 
25).  This was supported by a previous study that dopamine blockers lead to decline in 
OPs (10, 20).  RAR and RXR also present in amacrine cells (12, 13).  These may 
suggest that retinoids are associated with dopamine pathway in visual transduction in 
inner retinal layer cells.  In order to assess this hypothesis, gene expression of 
dopamine receptors in the retina and spontaneous locomotor activity, an indicator of 
dopamine level in the CNS, were additionally measured to afford collateral evidence for 
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the effects of VAD on the dopamine system.  Reversibility of these parameters was 
also evaluated after the 5 week recovery period. 
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3. MATERIAL AND METHODS 
3.1. ERG recording 
Before ERG recording, rats from each group were dark-adapted overnight and 
anesthetized with a combination of 40 mg/kg ketamine and 0.2 mg/kg xylazine by 
intramuscular injection.  The pupils were dilated with 0.5% tropicamide and 0.5% 
phenylephrine HCl.  Rats were placed on an electric heating set at 25 °C to prevent a 
decrease in body temperature until recording.  Dark adaptation was maintained 
throughout the recording.  ERG was recorded from the right eye of each animal using a 
contact lens type electrode (LS-W; Mayo, Aichi, Japan).  The recording electrode was 
placed in contact with the cornea, while a reference electrode was placed in the mouth.  
ERG responses were amplified, band-pass filtered between 0.5 to 200 Hz, by using a 
computer-assisted signal analysis system (MEB2200, Neuropack; Nihon Kohden, 
Tokyo, Japan).  Light stimuli from 0.0003 to 30 cd•s/m2 were provided by a SLS-3100 
(Nihon Kohden, Tokyo, Japan).  ERG response amplitudes and implicit times for a- 
and b-waves were determined based on the ISCEV standard (26).  OPs were also 
recorded from the right eye between 0.0003 and 3.0 cd•s/m2 of light stimuli with similar 
methods of the ISCEV standard (26).  A bandpass filter was set to 50–500 Hz.  The 
amplitudes and implicit time of OPs were determined as previously described (27).  
The amplitude of OPs was measured from the baseline to the peak of each wavelet, and 
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the implicit time was measured from the stimulus onset to the peak of each wavelet.  
Each ERG response was recorded with intervals of more than 30 seconds and was 
averaged for three flashes at each light stimuli level.   
3.2. Locomotor activity 
Spontaneous locomotor activity was measured using an automated motion analysis 
system (SCANET SV-20; MELQUEST, Toyama, Japan).  Animals (n = 6 for control 
and VAD rats) were tested in the SCANET cage for 30 min.  The following parameters 
were measured with similar methods as shown in previous study: Horizontal 
movements and the frequency of vertical movements caused by rearing (28).   
3.3. Quantitative PCR analysis 
Gene expression was investigated with quantitative reverse transcription PCR analysis 
(qRT-PCR).  Total RNA was extracted from whole unilateral retina using RNeasy mini 
kit (Qiagen, Hilden, Germany) at Week 10; and, converted to cDNA using a 
SuperScript® III (life technologies, Carlsbad, CA, US).  Gene expression levels were 
quantified using an ABI7900HT Sequence Detection System (life technologies, 
Carlsbad, CA, US).  The amounts of mRNA of Dopamine Receptor 1 (D1) and 2 (D2) 
were determined using specific probe sets (Assay ID: dopamine receptor D1A: 
Rn03062203_s1, dopamine receptor D2: Rn01418275_m1) of TaqMan Gene 
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Expression Assays (life technologies, Carlsbad, CA, US).  PCR was performed on 10 
ng of the obtained cDNA.  PCR conditions were 50 °C for 2 min; 95 °C for 10 min; 40 
cycles of 95 °C for 15 s, 60 °C for 1 min.   
3.4. Statistical analysis 
Student’s t-test was used to compare amplitude and implicit time of ERG components 
and the relative amplitude of b-wave and OPs to a-wave.  Wilcoxon analysis was 
applied to locomotor activity data.  In each analysis, differences were considered to be 
significant when P < 0.05.   
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4. RESULTS 
4.1. ERG recording 
Typical ERG wave forms which were recorded at 0.0003 to 30 cd•s/m2 at Week 10 are 
shown in Figure III-1.  The reduction of OPs in the VAD model could be noticed 
clearly from these traces.  The relationship between light intensity and amplitude or 
implicit time of a- and b-waves is shown in Figure III-2 (a) and (b), respectively.  The 
amplitude of b-wave was significantly decreased to approximately 50% of control value 
at light intensity higher than 0.003 cd·s/m2 at Week 10.  The amplitude of a-wave was 
also significantly decreased at light intensity higher than 0.3 cd·s/m2.  There were 
significant reductions in implicit time of b-waves in VAD rats compared to control at 
light intensity higher than 3.0 cd•s/m2.  Slight prolongations of implicit time of a-wave 
were observed at light intensity less than 0.03 cd·s/m2 with statistical significance.  
However, there were no differences in the implicit time of a-wave between VAD and 
control rats at light intensity higher than 3.0 cd·s/m2.  There were no differences in the 
amplitude and implicit time between VAD and control rats at Week 15 (Figure III-2 (c) 
and (d)).  
OPs of the VAD model were apparently smaller than those of control rats at Week 10 
(Figure III-1 (c) and (d)).  Summary of amplitudes and implicit times of OPs recorded 
at 0.03 to 3.0 cd•s/m2 is shown in Table III-1.  (OPs recorded at less than 0.01 cd•s/m2 
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were not listed on these tables because they could not be detected in most control 
animals.)  The mean amplitudes of OP1, 2, and 3 and summed OPs (ΣOPs = OP1 + 
OP2 + OP3 + OP4) in VAD rats were significantly decreased to 35% to 71% of control 
rats at Week 10.  In several VAD rats, loss of all OP wavelets was observed at less than 
0.3 cd•s/m2.  At 3.0 and 30 cd•s/m2, loss of a few OP peaks was noted.  The mean 
implicit time of OP1 and 2 were slightly prolonged at multi-intensity at Week 10.  
These changes returned to control levels at Week 15.  Relative amplitudes of b-wave 
(b/a) and ΣOPs (ΣOPs/a) to a-wave at 3.0 cd•s/m2 are shown in Figure III-3.  While the 
b/a of VAD rats was comparable to the control value, ΣOPs/a was significantly 
decreased at Week 10 (Figure III-3 (a)), and returned to the level of control after the 
recovery period (Figure III-3 (b)).  These data suggest that VAD influenced OPs more 
strikingly.  
4.2. Locomotor activity 
In the VAD model, horizontal movements tended to decrease, and the frequency of 
rearing was significantly lower at Week 10 compared with control rats (Figure III-4, 
Horizontal movement on Week 10, p = 0.31; rearing on Week 10, p = 0.04).  At Week 
15, no apparent differences between VAD and control rats were observed in these 
parameters (Figure III-4, Horizontal movement on Week 15, p = 0.438; rearing on Week 
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15, p = 0.485). 
4.3. Gene expression of dopamine receptors 
The mRNA of D1 and D2 in retina were investigated with qRT-PCR at Week 10 (Figure 
III-5).  The expression levels of both D1 and D2 in VAD rats were slightly decreased 
compared with control rats, but there was no statistical significance (D1: p = 0.13, D2: p 
= 0.16).   
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5. DISCUSSION 
Retinal Function of the Vitamin A Deficient Rat model 
It has been previously shown that VAD causes dysfunction of photoreceptor cells (29), 
where VAD induces a decrease in 11-cis retinal which is necessary for the synthesis of 
rhodopsin.  This leads to insufficient phototransduction from light to electric signals 
and decline of the a-wave in ERG.  The present results were consistent with these 
changes.  However, the VAD model showed that only functional impairments of the 
retina were induced by feeding Vit A(-) diet to BN rats for 10 weeks since there was no 
histopathologic change in CHAPTER II and reversible ERG change in a- and b-waves 
and OPs.   
In outer retinal layer cells, the electric stimulus is transmitted to and activates bipolar 
cells by hyperpolarization of photoreceptor cells.  The activation of bipolar cells is 
reflected in the b-wave in ERG (3).  Accordingly, it is considered that the magnitude of 
the b-wave depends on that of the a-wave.  No difference in the b/a ratio between 
control and the VAD model in the present study suggests that the there was no 
interference in the signal transmission from photoreceptor cells to bipolar cells by VAD.  
The signal from bipolar cells subsequently activates the inner retinal layer cells such as 
amacrine cells.  The reduction of a-waves may lead to the decreased input to bipolar 
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cells, and then reduce signal transduction from bipolar cells to amacrine cells which 
generate OPs.  Therefore, there may be a corresponding decrease in OPs following the 
reduction of a-wave.  In the present study, there was decreased amplitude of a-wave 
with strong light intensities in the VAD model with decreases in OPs at Week 10.  
However, analysis showed a significant reduction of ΣOPs/a in VAD rats at Week 10, 
despite having no changes in b/a, indicating a greater magnitude of reduction in OPs 
than the reduction secondary to a-wave reduction alone.   
 
Involvement of Dopamine Pathway in Inner Retinal Layer Cell Functions 
In the CNS, AT- retinoic acid and 9-cis retinoic acid are known to regulate gene 
expression of dopamine receptors via nuclear receptors, RAR and RXR (22, 23, 24, 30).  
AT-retinoic acid was decreased with statistical significance at Week 10.  In addition, 
the greater decrease in 9-cis retinoic acid was suggested by the remarkable reduction of 
endogenous precursors, 9-cis retinol and retinal in CHAPTER II (31).  The retinoid 
receptor mutant mice show decreases in locomotor activity which is an indication of 
dopamine activities in the CNS (14).  The significant reduction in rearing count in the 
present study indicates that the similar decrease in dopamine receptors by retinoids is 
present in the VAD model.  The other previous study have reported that dopamine acts 
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as one of the important chemical messengers among amacrine cells or between 
amacrine cells–ganglion cells in the retina and activates the dopamine pathway via D1 
and D2 (9).  Based on the decreases in retinal retinoid and rearing count, I speculated 
that a VAD state induces down-regulation of dopamine receptors in the inner retinal 
layer cells with decreases in OPs.  There was no statistically significant difference in 
mRNA levels of D1 and D2 in the retina between the VAD model and control rats, 
although there were tendencies of reduction in these levels.  This may indicate that 
additional factors contribute to the decline of OPs in VAD rats.   
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6. FIGURES AND TABLES 
Table III-1. Summary of the amplitude and implicit time of each OP wavelet and 
summed OPs at weeks 10 and 15 
(A) Week 10 
 
 
Amplitude (µV) Implicit time (msec) 
OP1 OP2 OP3 OP4 ΣOP OP1 OP2 OP3 OP4
0.03 cd·s/m
2
 
control 
AV 34.6 83.8 45.8 6.8 170.9 30.1 35.6 42.0 52.4
SD 5.2 12.4 18.7 10.9 34.9 1.2 1.0 1.2 3.6
VAD 
AV 15.3** 37.8** 21.6** 2.6 77.2** 34.8** 40.6** 47.2** 55.7
SD 12.9 29.7 16.7 5.3 59.4 2.6 2.7 3.2 5.1
0.3 cd·s/m
2
 
control 
AV 75.8 134.8 44.8 3.4 258.8 26.1 31.6 39.1 50.0
SD 17.8 30.6 12.7 3.4 58.8 2.3 2.2 2.2 3.3
VAD 
AV 32.6** 68.6** 31.8* 5.5 130.9** 28.9** 34.6** 41.0 50.0
SD 19.6 26.4 21.3 8.9 64.0 2.8 2.6 3.4 5.3
3.0 cd·s/m
2
 
control 
AV 120.1 161.6 50.4 3.2 335.4 24.3 30.3 38.3 48.1
SD 27.2 38.3 13.9 2.6 78.8 2.2 2.4 2.5 1.7
VAD 
AV 45.4** 77.3** 33.1** 5.1 161.0** 26.9* 32.6* 39.3 47.1
SD 25.3 34.9 19.6 6.7 73.9 3.3 2.9 4.1 4.2
30.0 cd·s/m
2
 
control 
AV 129.5 181.5 54.5 5.8 371.4 22.4 28.7 37.1 48.0
SD 28.3 45.8 15.1 3.4 87.6 2.7 2.6 2.6 2.8
VAD 
AV 45.4** 84.3** 36.1** 4.6 170.4** 24.6* 30.5* 37.5 45.7
SD 23.2 35.9 20.9 5.6 73.8 2.5 2.4 3.0 3.9
AV: Average, SD: Standard Deviation 
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(B) Week 15 
 
 
Amplitude (µV) Implicit time (msec) 
OP1 OP2 OP3 OP4 ΣOP OP1 OP2 OP3 OP4
0.03 cd·s/m2 
control 
AV 36.2 67.2 38.2 3.3 144.8 29.9 35.2 41.5 51.1
SD 20.0 40.8 21.7 5.3 80.2 0.9 1.2 1.1 2.1 
VAD 
AV 30.3 67.7 41.7 4.0 143.7 28.9 34.8 41.3 51.0
SD 17.5 37.4 25.7 5.5 80.0 0.7 0.5 0.7 2.1 
0.3 cd·s/m2 
control 
AV 76.8 139.7 45.3 10.3 272.2 25.0 30.5 38.3 47.6
SD 16.7 32.0 14.5 6.9 59.5 0.8 0.7 1.8 1.8 
VAD 
AV 73.8 139.0 40.5 6.0 259.3 25.0 30.3 38.4 49.4
SD 16.9 27.6 11.1 3.6 55.1 0.5 0.4 0.8 0.7 
3.0 cd·s/m2 
control 
AV 126.8 174.8 54.3 8.5 364.5 23.4 29.1 37.5 46.6
SD 19.8 40.3 13.8 4.8 72.5 0.6 0.6 1.6 1.7 
VAD 
AV 117.8 165.2 45.3 2.5 330.8 23.0 28.9 37.5 47.9
SD 24.7 26.9 14.6 3.6 66.4 0.4 0.7 0.7 1.3 
30.0 cd·s/m2 
control 
AV 137.2 194.5 54.7 6.3 392.7 21.5 27.5 36.1 46.5
SD 24.2 43.8 15.0 5.5 79.8 0.5 0.6 0.8 1.4 
VAD 
AV 124.7 181.5 45.8 3.2 355.2 21.1 27.2 36.0 46.6
SD 26.4 34.4 12.8 1.5 70.5 0.3 0.5 0.5 1.0 
AV: Average, SD: Standard Deviation 
 
The amplitude and implicit time of each OP wavelet and summed OPs in vitamin A 
deficient rats were compared with those of control rats. The mean and standard 
deviation of each wavelet and ΣOPs were shown at Weeks 10 and 15 in (A) and (B), 
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respectively. Bold figures mean the values have statistical significance. *: p < 0.05 and 
**: p < 0.01 versus control with student’s t-test. 
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Figure III-1. Typical ERG wave forms of control and vitamin A deficient rats at 
Week 10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dark adapted ERG wave forms produced by 0.0003 to 30 cd•s/m2 of light stimuli in (a) 
control and (b) vitamin A deficient rats are shown.  Wave forms of OPs produced by 
0.0003 to 3.0 cd•s/m2 of light stimuli are shown in (c) control and (d) vitamin A 
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deficient rats. 
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Figure III-2. The relationships of the amplitude and the implicit time of ERG 
components to light intensity at Weeks 10 and 15. 
 
Mean responses of 6 to 8 rats to seven flashes of 0.0003 to 30 cd•s/m2 are shown.  Bars, 
SD.  (a and c) Amplitude and (b and d) implicit time of a- and b-waves at Weeks 10 (a 
and b) and 15 (c and d).  **: p<0.01 
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Figure III-3. The effect of vitamin A deficiency on the relative amplitude of b-wave 
and ΣOPs to that of a-wave.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mean values of b/a and ΣOPs/a at Week 10 (a) and 15 (b) are shown.  Bars, SD.  **: 
p < 0.01 versus control with student’s t-test. 
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Figure III-4. Comparison of locomotor activities between control and vitamin A 
deficient rats. 
Mean values reveals total frequency of horizontal movements (A) and the frequency of 
rearing (B) with the SD at Weeks 10 (A) and 15 (B). *: p < 0.05 versus vehicle control 
with Wilcoxon statistical analysis.  
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Figure III-5. The expression levels of both dopamine 1 and 2 receptors in control 
and vitamin A deficient rats at Week 10. 
Mean values of mRNA levels of dopamine 1 and 2 receptors are shown with SD (n=3) 
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CHAPTER IV   
Concluding remarks 
 
VAD is well known to cause visual impairments including prolonged dark adaptation 
and night blindness based on dysfunction of photoreceptor cell.  Associated with this 
mechanism, human and animals with VAD show that a-wave reduces depending upon 
the stage of the VAD disease in ERG recording (3, 5).  Similar results were observed in 
the present model with early stage of VAD disease.  Additionally, there was reduced 
OPs indicative of inner retinal layer cell dysfunction in this research.  Amacrine cells 
are releasing and receiving several neurotransmitters, including dopamine, GABA, 
glycine, and acetylcholine in order to stimulate other amacrine or ganglion cells (10, 30, 
32).  The significant reduction of ΣOPs/a in the VAD model possibly indicates that 
VAD influences not only functions of photoreceptor cells but also signal transduction of 
inner retinal layer cells via these transmitters.  Here, I speculated that a down-regulated 
dopamine pathway is mainly implicated in the inner retinal layer cell dysfunction since 
retinoic acid is involved in regulation of dopamine receptors.  However, there was no 
statistical significant difference in mRNA level of D1 and D2 in retina between normal 
and the VAD model rats.  This may indicate that other factors contribute to the decline 
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of OPs in VAD rats, although the possibility of the involvement of dopamine pathway 
cannot be entirely ruled out since there were reduction of rearing count and the tendency 
of decreased mRNA levels of D1 and D2.  For example, a previous report indicated 
that retinoic acid is required for activation of an enzyme that converts glutamate to 
GABA (33).  The decline of OPs in the VAD model may be affected by a variety of 
factors associated with abnormalities in the levels of neurotransmitters, and decreased 
photoreceptor output.   
In the present study, I have shown for the first time that VAD affects the generation of 
OPs.  The decreased OPs in the present study possibly reflect reduced contrast 
sensitivity in patients with VAD and may also be applied for prediction of, or for early 
detection of, other conditions with reduced contrast sensitivity.  The model used in the 
present study may also afford an animal model for the research associated with OPs 
abnormality.   
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